A12 Immunotherapy

Topic

Immunotherapy harnesses the patient's own immune system to recognize and destroy tumor cells, rather than attacking them directly with cytotoxic agents. Its main modalities include immune checkpoint inhibitors, genetically modified T cells, and cytokines. A distinctive feature is its ability to generate immunological memory, allowing certain anti-tumor responses to persist for years after treatment ends.

One modality involves extracting T cells from the patient and genetically modifying them to express an artificial receptor capable of recognizing a specific antigen present on tumor cells. After reinfusion, these lymphocytes activate and proliferate upon encountering cells expressing that antigen. The greater the tumor burden, the more extensive their initial expansion and destructive activity can be, although the elimination capacity of each lymphocyte eventually reaches a plateau. To control the tumor, the overall rate of destruction must exceed the tumor's proliferation rate; if the population of modified lymphocytes fails to reach a sufficient level, the tumor may escape treatment.

Intense activation of these lymphocytes and other immune cells can trigger cytokine release syndrome. Large quantities of mediators—such as interleukin-6, interleukin-1, and interferon-gamma—are released, causing fever, hypotension, and impaired oxygenation, and, in severe cases, a systemic inflammatory response. The severity of the syndrome increases with immune activity and the tumor mass being targeted. Tocilizumab blocks the interleukin-6 receptor, allowing this complication to be managed without preventing the modified lymphocytes from continuing to attack the tumor.

Another strategy employs immune checkpoint inhibitors. Some tumors express proteins capable of activating inhibitory receptors on tumor-infiltrating cytotoxic T cells, thereby reducing their proliferation and destructive capacity. This inhibitory signal increases with the amount of tumor protein, eventually approaching a saturation level. Checkpoint inhibitors are antibodies that interfere with this interaction, thereby reducing the immunological "brake" and allowing lymphocytes to regain their antitumor activity.

Response to these treatments is linked to the tumor's mutational burden. The more mutations a tumor cell accumulates, the greater the number of abnormal proteins the immune system can recognize as distinct from normal ones. This provides more potential targets for T lymphocytes and can enhance the response to checkpoint inhibitors.

The interplay between immunotherapy and radiotherapy is also evident in the abscopal effect. Occasionally, local irradiation of a tumor leads to the regression of distant metastases that did not receive radiation. Local destruction releases tumor antigens capable of activating specific T lymphocytes; these subsequently circulate throughout the body and attack tumor cells located elsewhere. While this phenomenon is rare with radiotherapy alone, it can be amplified by combining it with checkpoint inhibitors, as the latter remove some of the constraints limiting activated lymphocytes.

Overall, immunotherapy aims to tip the balance between tumor growth and immune response in the patient's favor. Modified T lymphocytes provide targeted recognition and expansion against the tumor; checkpoint inhibitors unleash previously suppressed immune responses; and radiotherapy can supply antigens that stimulate a systemic response. At the same time, immune-related toxicity—particularly cytokine release syndrome—must be monitored.

The choice and combination of these strategies depend on the tumor's characteristics, antigens, inhibitory mechanisms, and mutational burden. Furthermore, the persistence of certain therapeutic antibodies for weeks allows for less frequent dosing. Thus, immunotherapy seeks not only to destroy the existing tumor but also to establish an immune response capable of remaining active and—through immunological memory—continuing to protect the patient after treatment has concluded.

ID:2275